Combination treatment for recurrent endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (camrelizumab and anlotinib) for patients with a specific type of endometrial cancer that has returned or spread. The drug combo aims to boost your immune system to fight the cancer while also cutting off its blood supply. It is for patients whose tumor has a certain genetic feature and who have already tried chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have endometrial cancer that has come back or is advanced and is not curable with surgery or radiation.
- You must have had at least one prior treatment with platinum-based chemotherapy (like carboplatin or cisplatin).
- Your tumor must test positive for a genetic feature called mismatch repair deficiency (MMRd) and also have MLH1 methylation (a specific genetic change).
- You must not have received certain immunotherapies (anti-PD-1 or anti-PD-L1) in the past.
- You must be physically well enough to care for yourself (ECOG score 0-2) and have adequate organ function.
- You should not have active infections, uncontrolled heart issues, or other serious illnesses that would interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.